Company Profile

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital, a leader in neuromuscular disease gene therapy discovery and clinical translation.